Panel Backs Limited New Olaparib Use in Prostate Cancer

An expert panel recommended restricting the expanded first-line indication to patients whose metastatic castration-resistant prostate tumors have BRCA mutations.

Related Keywords

Jorgej Nieva ,Terrencem Kungel ,Los Angeles ,Ravia Madan ,Susan Galbraith ,Cancer Research ,National Cancer Institute ,Drug Administration ,Oncologic Drugs Advisory Committee ,University Of Southern California ,Astrazeneca ,Southern California ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Prostate ,Breast Cancer ,Alignant Breast Neoplasm ,Ovarian Cancer ,Alignant Ovarian Neoplasm ,Cancer ,Alignant Neoplasia ,Arcinoma ,Prostatic ,Brca ,Malignant Pancreatic Neoplasm ,Pancreatic Cancer ,Ancer Pancreatic ,Toxicology ,Genomics ,Genomic Medicine ,Edicine Genomic ,Tumor ,Biomarker ,Iological Marker ,Blood Transfusi ,